KDR and renal cell carcinoma: Given the evidence from preclinical and early clinical studies, a randomized phase 3 trial (METEOR) was conducted to compare the efficacy and safety of cabozantinib with standard-of-care everolimus in patients with advanced RCC whose disease had progressed during or after prior VEGFR TKI therapy [21••, 22••].